Lv3
360 积分 2022-05-17 加入
Upadacitinib: First Approval
2天前
已完结
Peficitinib: First Global Approval
3天前
已完结
Peficitinib: First Global Approval
3天前
已关闭
Baricitinib: First Global Approval
3天前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
6天前
已完结
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
6天前
已完结
Tirzepatide for Weight Reduction in Chinese Adults With Obesity
8天前
已完结
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
8天前
已完结
Effectiveness of intermittent pneumatic compression in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial
8天前
已完结
Clinical effectiveness of semaglutide on weight loss, body composition, and muscle strength in Chinese adults
10天前
已完结
皖公网安备34019202002308
